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The balance between effective tumor necrosis factor (TNF) blockade to control aggressive autoimmune disease
states and adequate remaining TNF activity to confer immunoprotection against infections such as tuberculosis
is an important and complex issue. An increased scientific understanding of how each of the TNF antagonist
agents affects the complex interactions of the inflammation cascade and apoptosis, and whether the effects are
modulatory or destructive, is needed. The data presented in this supplement highlight the need for further
research into these key areas, and illustrate our current understanding of the mode of action of TNF blockers as
only the tip of the iceberg.
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There remain many unanswered questions regarding tumor
necrosis factor (TNF) antagonists and their effects on the
immune system and the patient. Although neutralizing TNF
can alleviate symptoms of inflammatory diseases, there
appear to be implications for patients’ susceptibility to
infections such as tuberculosis. Many of the immune-related
diseases have been associated with elevated levels of TNF,
but as the animal models with deleted genes presented
suggest, levels of TNF that are insufficient may compromise
innate immunity and confer greater risks of infections. It may
be that therapies that neutralize TNF bioactivity completely,
while potentially active in a wider range of diseases, move
TNF levels below an immunoprotective window. The relative
importance of serum versus tissue concentrations of TNF is
also unknown, and whether this varies in different disease
states and even different tissues. And, although TNF is a
major cytokine that is involved in a number of inflammatory
diseases, there are obviously other immunomodulatory
cytokines of which the same questions should be asked –
IFN-g, IL-12, IL-23, IL-15, and lymphotoxin-a, while clearly
important, have roles that need further elucidation.
Perhaps, a better understanding of the differences between
the two classes of anti-TNF therapies might also provide clues
as to the mechanisms behind these inflammatory diseases, as
well as the susceptibility to bacterial and opportunistic
infections. The elucidation of the crystallographic structures
has shed light onto the potential interactions between TNF
and fusion protein or antibody, but many questions remain
unanswered. For example, the finding by Kohno et al.
(published in this supplement) that, in vitro, the anti-TNF
monoclonal antibodies formed large complexes with TNF
whereas the fusion protein did not, has yet to show clinical
implications; does this mean that the relevance of the
complexes might only be in mediating cell death by
antibody-dependent cellular cytotoxicity or complement-
dependent cytotoxicity, or are there other implications that
are undiscovered as yet? Cell death and apoptosis both need
further exploration; whereas TNF receptor p55 and, to a
lesser extent, p75 are known to be involved, the multiple and
complicated interactions between the two TNF cell-surface
receptors are also not understood fully.
Data reviewed in this supplement suggested that tubercu-
losis risk might be associated with inhibition of T cell
activation and IFN-g production, but not with effects on IL-10.
What is the basis for these cytokine-specific downstream
effects? Are they mediated by binding to soluble or
membrane-associated TNF? Is their locus the T cell or the
antigen-presenting cell? If the T cell, do TNF antagonists alter
the ability of T cells to recognize and respond to foreign
antigen, and do the two classes of TNF antagonists have
different effects? Two reports have indicated that TNF
antagonists induce regulatory T cells (Wu et al., 2002;
Ehrenstein et al., 2004), but is this finding sufficient to explain
the susceptibility to infections with intracellular pathogens?
There are other activities that need to be examined, including
the role of TNF-a antagonists on antigen presentation and on
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the induction of cytokines that may block the expression of
cellular immunity.
Optimal strategies to prevent and manage infectious
complications of TNF blockade remain incompletely defined.
For example, Kaur and Mahl (in press) have identified 84
cases of Pneumocystis jiroveci (carinii) pneumonia in patients
with inflammatory bowel disease treated with infliximab.
Although the cases appear to be infrequent, a mortality rate of
27% has been reported (Kaur and Mahl; T Mahl (Personal
communication with R Wallis)). Prophylaxis with trimetho-
prim-sulfa has been highly effective in preventing Pneumo-
cystis pneumonia in persons with HIV infection. Presently,
there are no strategies for screening and/or prevention of
fungal infections such as histoplasmosis and coccidioidomy-
cosis. Even for tuberculosis, a complication for which the
relative risks of the TNF blockers have been best defined, and
for which screening and prophylaxis has been most success-
ful, many questions remain. If tuberculosis is diagnosed and
anti-TNF therapy is discontinued, how quickly must it be
stopped and when may it be resumed? Will existing strategies
be effective in regions of high, ongoing tuberculosis
transmission? These questions will become increasingly
important as these drugs become available globally.
Considerations relevant to patients with inflammatory
diseases are not limited to infections, of course. Other
potentially important fields of study are the effect of TNF
blockade on related diseases such as inflammatory-mediated
cardiovascular disease, metabolic syndrome, or psoriatic
arthritis; is it possible to affect the likelihood of developing
these related diseases by treating an existing inflammatory
disorder with TNF blockade? To optimize patient care, it
would be beneficial to develop clinically practical assays that
measure concentration of drug, gene regulation in cells and
tissues, and/or biomarkers in serum to predict clinical
response to TNF blockade or to identify patients likely to
experience adverse events. As the population of patients who
are treated by TNF antagonism expands, it will also be critical
to further understand the effect of TNF blockade, if any, on
neonates and children.
It is striking that these basic questions regarding mechan-
ism of action are still being studied 8 years and 1 million
treated patients after these drugs were first approved.
However, one anticipates that the ongoing characterization
of the differential actions of the TNF antagonists may
continue to contribute to our understanding of the diverse
clinical outcomes. Translational research – the process of
moving from clinical signal to molecular underpinnings, and
back again – requires a continued dialogue between the
clinician and the scientist. Learning why and how will ensure
the best care for patients who live with these chronic
diseases.
CONFLICT OF INTEREST
Research grant recipients from Wyeth: Robert S. Wallis, Alice Gottlieb.
Consultants to Amgen: Robert S. Wallis, George Deepe, Alice Gottlieb.
Consultant to Wyeth: Alice Gottlieb. Amgen employees: James Louie, Francis
Dann, Elizabeth Thompson. Grant recipients from Amgen: George Deepe,
Alice Gottlieb, JoAnne Flynn. None of the authors received honoraria in
connection with the production of this paper, but all authors have received
honoraria in connection with the production of other papers in this
supplement. Honoraria in respect of Alice Gottlieb’s contribution went to
Pratt Dermatology, Tufts-New England Medical Center, Boston, MA.
REFERENCES
Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA et al.
(2004) Compromised function of regulatory T cells in rheumatoid
arthritis and reversal by anti-TNF-alpha therapy. J Exp Med 200:277–85
Kaur N, Mahl TC. Pneumocystis jiroveci (carinii) pneumonia after infliximab
therapy: a review of 84 cases. Dig Dis Sci. (in press)
Wu AJ, Hua H, Munson SH, McDevitt HO (2002) Tumor necrosis factor-alpha
regulation of CD4+CD25+ T cell levels in NOD mice. Proc Natl Acad Sci
USA 99:12287–92
www.jidonline.org 47
FJ Dann et al.
Next Steps
